Malignant lymphoma of the oral cavity: A single-center study of 28 cases. Issue 6 (November 2022)

• Record Type: Journal Article
• Authors: Okamura, Takeshi; Izumo, Toshiyuki; Ishikawa, Ayataka; Nishimura, Yu; Kubota, Nobuko; Yagihara, Kazuhiro
• Is Part Of: Journal of oral and maxillofacial surgery, medicine, and pathology. Volume 34:Issue 6(2022)
• Page Start: 698
• Page End: 703
• Publication Date: 2022-11
• Subjects: Malignant lymphoma -- Oral cavity -- Pathology -- Therapy -- Survival rate; ALK anaplastic lymphoma kinase -- DLBCL diffuse large B-cell lymphoma -- NHL non-Hodgkin lymphoma -- NK natural killer -- WHO World Health Organization; Mouth -- Surgery -- Periodicals; Face -- Surgery -- Periodicals; Maxilla -- Surgery -- Periodicals; Oral medicine -- Periodicals; Mouth -- Diseases -- Pathogenesis -- Periodicals; Surgery, Oral -- Periodicals; Oral Medicine -- Periodicals; Pathology, Oral -- Periodicals; Face -- Surgery; Maxilla -- Surgery; Mouth -- Diseases -- Pathogenesis; Mouth -- Surgery; Oral medicine; Electronic journals -- Sciences; Electronic journals -- Medicine; Periodicals; 617.522059
• DOI: 10.1016/j.ajoms.2022.04.003
• Languages: English
• ISSNs: 2212-5566

Abstract

Abstract: Objectives: This study aimed to determine the clinicopathological features, treatment methods and prognosis in patients with malignant lymphoma of the oral cavity. Methods: We retrospectively examined 28 cases of malignant lymphoma of the oral cavity based on the novel World Health Organization pathological classification. Results: The most common primary site was the upper gingival area (32.1%) and the most frequent initial symptom was painless swelling (48.5%); 7.1% of cases were stage III and 21.4% were stage IV according to the Ann Arbor classification. The most common histologic type was diffuse large B-cell lymphoma. Clinically, 14.3% of cases were classified as highly aggressive, and three-quarters of these cases were ulcerated. The most common type of chemotherapy was R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), which was used in 28.6% of patients. Five-year overall survival was 69.7% for all cases and 53.5% for those with diffuse large B-cell lymphoma. Conclusions: Patients with an Ann Arbor disease classification of stage III or IV and histologically aggressive disease are not uncommon and have poor prognosis. Therefore, prompt biopsy is needed for painless swelling of the upper gingiva to perform differential diagnosis of malignant lymphoma of the oral cavity.